61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Coherus Biosciences Inc
Closed
Sector Healthcare
1.12 -2.61
Overview
Share price change
24h
Min
1.03
Max
1.17
Income | -11M |
|---|---|
Sales | 71M |
EPS | -0.09 |
Profit margin | -15.191 |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +503.45 upside |
Next Earnings | 12 Mar 2025 |
|---|
Market Cap | 4.5M 278M |
|---|---|
Previous open | 3.73 |
Previous close | 1.12 |
News Sentiment
By Acuity
50%
50%
170 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Coherus Biosciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Coherus Biosciences Inc Forecast
Price Target
By TipRanks
503.45% upside
12 Months Forecast
Average 7 USD 503.45%
High 8 USD
Low 6 USD
Based on 6 Wall Street analysts offering 12 month price targets forCoherus Biosciences Inc - Dist in the last 3 months.
Sentiment
By Acuity
170 / 393 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Coherus Biosciences Inc
Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.
